Overview
- The King's College London team publicly reported the Efflux Resistance Breaker concept in a paper published on Friday, May 29, 2026, describing a chemical redesign that makes antibiotics less vulnerable to bacterial efflux pumps.
- Efflux pumps are protein machines that eject drugs from bacterial cells and lower intracellular antibiotic levels, and the new design builds resistance-breaking features into the antibiotic molecule so it stays inside bacteria at higher concentrations.
- In the study the researchers applied the approach to fluoroquinolones and showed improved intracellular accumulation, reduced efflux susceptibility, preserved antibacterial potency in vitro, and efficacy in mouse infection models.
- The work is a preclinical proof of concept: the team intends to commercialize the platform and advance candidates toward human trials, but no clinical testing or regulatory approvals have been reported yet.
- The result is notable because it offers a different path from past efforts to pair antibiotics with separate efflux pump inhibitors, and it could both inform next-generation drug design and help revive older antibiotics as global antimicrobial resistance rises.